0001209191-23-059558.txt : 20231222 0001209191-23-059558.hdr.sgml : 20231222 20231222161728 ACCESSION NUMBER: 0001209191-23-059558 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231220 FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alder Matthias CENTRAL INDEX KEY: 0001370820 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40237 FILM NUMBER: 231510032 MAIL ADDRESS: STREET 1: C/O MICROMET, INC. STREET 2: 6707 DEMOCRACY BLVD., STE. 505 CITY: BETHESDA STATE: MD ZIP: 28017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gain Therapeutics, Inc. CENTRAL INDEX KEY: 0001819411 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851726310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4800 HAMPDEN LANE STREET 2: SUITE 200 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (301) 500-1556 MAIL ADDRESS: STREET 1: 4800 HAMPDEN LANE STREET 2: SUITE 200 CITY: BETHESDA STATE: MD ZIP: 20814 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-20 0 0001819411 Gain Therapeutics, Inc. GANX 0001370820 Alder Matthias C/O GAIN THERAPEUTICS, INC. 4800 MONTGOMERY LANE, SUITE 220 BETHESDA MD 20814 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-12-20 4 M 0 637 A 5492 D Common Stock 2023-12-21 4 S 0 206 2.46 D 5286 D Restricted Stock Units 2023-12-20 4 M 0 637 0.00 D Common Stock 637 7013 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4602 to $2.485 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. /s/ Matthias Alder 2023-12-22